

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://gov.uk/mhra)

## Decision Cover Letter

### Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100579-PIP01-22-M04

### Scope of the Application

#### Active Substance(s)

MARIBAVIR

#### Condition(s)

Treatment of cytomegalovirus (CMV)

#### Pharmaceutical Form(s)

Film-coated tablets; Powder for oral suspension

#### Route(s) of Administration

ORAL USE

#### Name / Corporate name of the PIP applicant

Takeda UK Limited

#### Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Takeda UK Limited submitted to the licensing authority on 19/12/2024 13:58 GMT an application for a

The procedure started on 19/02/2025 10:16 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100579-PIP01-22-M04

Of 14/03/2025 10:10 GMT

On the adopted decision for MARIBAVIR (MHRA-100579-PIP01-22-M04) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a for MARIBAVIR, Film-coated tablets; Powder for oral suspension , ORAL USE .

This decision is addressed to Takeda UK Limited, 1 Kingdom Street, Paddington, UNITED KINGDOM, W2 6BD

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Not applicable.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of cytomegalovirus (CMV) infection.

#### 2.2 Indication(s) targeted by the PIP:

Treatment of cytomegalovirus (CMV) in paediatric patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age.

### 2.4 Pharmaceutical Form(s):

Film-coated tablet Powder for oral suspension

### 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of a powder or tablet for oral suspension.
Non-Clinical Studies	1	Study 2 (R11007M-SHP620) Definitive juvenile toxicity study in rats to evaluate potential gastrointestinal toxicity.
Clinical Studies	3	Study 3 (SHP620-302) Double-blind, randomised, double-dummy, active-controlled trial to evaluate pharmacokinetics, safety, efficacy and acceptability of maribavir compared to valganciclovir for the treatment of asymptomatic CMV infection in adolescent and adult haematopoietic stem cell transplant (HSCT) recipients. Study 4 deleted in EMEA-00353-PIP02-16-M01. Study 5 (TAK-620-1019) Open-label, randomised, single dose, three-treatment, three-period crossover study to assess the relative bioavailability, palatability, and safety/tolerability of the two candidate paediatric powder for oral suspension formulations of maribavir versus the adult tablet of maribavir in healthy adult volunteers. Study 6 (TAK-620-2004) Open-label, single-arm, repeated dose trial to evaluate pharmacokinetics, safety, tolerability, antiviral activity and acceptability/palatability of maribavir for the treatment of CMV infection in children and adolescents from birth

		to less than 18 years of age who have received a HSCT.
<b>Extrapolation, Modeling &amp; Simulation Studies</b>	2	Study 7 Modelling and Simulation study to support paediatric dose finding and the extrapolation of use of maribavir for the treatment of CMV infection in children from birth to less than 18 years of age. Study 8 Extrapolation study to support the use of maribavir for the treatment of CMV infections in children and adolescents from birth to less than 18 years of age who have received a SOT
<b>Other Studies</b>	0	Not applicable.
<b>Other Measures</b>	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	NO
<b>Date of completion of the paediatric investigation plan:</b>	31/05/2028
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	YES